Investigation of Annonaceae Acetogenins for Inhibition of Dengue Viral Protease using in silico Docking Studies

Authors

  • Pooja Karkera
  • Mangala K.J.
  • Ravikumar Y.S.

Abstract

Dengue viruses (DENVs) cause severe and widespread epidemics of diseases such as dengue fever and dengue hemorrhagic fever/dengue shock syndrome. Unfortunately, there is at present neither prophylaxis nor specific treatment to cure the disease and thus it is need of the hour to develop new antiviral therapeutic agents to combat diseases caused by DENV. Non-structural protein NS3 play a major role in the processing of polyprotein and replication of the virus. Inhibitors of NS3/2B may disrupt two separate processes relevant to the suppression of DENV infection. So far many plant derived compounds have been investigated for their possible dengue viral inhibitory property; however, Annonaceae acetogens are not explored for developing inhibitors for dengue viral replication. Hence, in view of this, first we selected two plants reported to contain Acetogens and a library of 15 acetogens present in selected plants was constructed and docked against the NS3 protease to obtain lead molecule. Asiminacin showed the best interaction with the protein. However, their possible inhibitory effect against dengue viral protease can be confirmed by using High Throughput NS3 protease assay.

 

Keywords: acetogenins, Dengue virus (DENV), protease, molecular docking

Cite this Article

Pooja Karkera, Mangala K.J., Ravikumar Y.S. Investigation of Annonaceae Acetogenins for Inhibition of Dengue Viral Protease using in silico Docking Studies. Research & Reviews: A Journal of Life Sciences. 2019; 9(Issue 1 Special): 47s–52s.

Downloads

Published

2019-06-25

Issue

Vol. 9 No. 1 (2019)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.